Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FKC889 in Relapsed/Refractory Mantle Cell Lymphoma
ChiCTR2200058983Phase 2Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jun 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of FKC889 in mantle cell lymphoma (MCL), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Optimal objective response rate (best overall response rate, bORR). Started Jun 2022; status: recruiting.
02
Drugs
FKC889
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on ChiCTR2200058983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058983.